We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

QuidelOrtho

Develops, manufactures and markets rapid diagnostic tests that focus on infectious diseases, reproductive health, and... read more Featured Products: More products

Download Mobile App





Quidel Showcases Comprehensive Suite of COVID-19 Testing Solutions at MEDLAB Middle East 2021

By LabMedica International staff writers
Posted on 21 Jun 2021
Quidel Corporation (San Diego, CA, USA) showcased its comprehensive suite of COVID-19 testing solutions at MEDLAB Middle East 2021 that took place in Dubai from 21-24 June.

Quidel introduced its new Sofia Q Fluorescent Immunoassay Analyzer, a powerful clinical diagnostic device in a very compact size, to be used with its Sofia SARS Antigen FIA Test Cassettes to diagnose COVID-19. More...
Sofia Q uses advanced fluorescence detection with an ultraviolet LED energy source and collects hundreds of data points on the test strip contained inside the Test Cassette. Quidel recently received an amended Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) allowing the company to market Sofia Q, its latest addition to the Sofia and Sofia 2 line of Fluorescent Immunoassay Analyzers (FIA).

In addition to the Sofia Q, Quidel also exhibited other rapid diagnostic instrumented systems, including Sofia 2, and Sofia. Also on display were Quidel’s Sofia assays for rapid antigen COVID-19 diagnosis, including Sofia 2 SARS Antigen FIA and Sofia 2 Flu + SARS Antigen FIA, currently under EUA by the FDA. At MEDLAB Middle East 2021, Quidel also highlighted its other FDA-cleared and CLIA-waived tests, including Influenza A and B, Respiratory Syncytial Virus (RSV), Group A Strep, and a 15-minute finger-stick whole blood test for Lyme Disease.

Related Links:
Quidel Corporation


Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gel Cards
DG Gel Cards
Gold Member
Hematology System
Medonic M16C
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The partnership with LLS expands access to Lucent’s non-invasive blood-based biomarker tests for early detection of cognitive diseases (photo courtesy of Adobe Stock)

New Partnership Brings Alzheimer’s Blood Biomarker Test to Community Screening Network

Lucent Diagnostics, a brand of Quanterix Corporation, has partnered with Life Line Screening (LLS) to offer Lucent’s non‑invasive, blood‑based biomarker test across the United States. Programs are... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.